NEO, the First Approved Implantable BCI, and the NSCEB's Gap List of 2 September 2026: What China Has in Place, What the US Lacks, and a 1,951-Character Mandarin Claim With No Located Paper

Quentir Medicine Monitor

Evidence-based insights for quantum medicine.

A person with a cervical spinal cord injury can imagine closing a hand for years without the hand moving. The brain still issues the command; the spinal cord no longer carries it. A brain-computer interface reads the command above the break and sends it to a machine that does the closing. Regulatory approval, manufacturing capacity and reimbursement all decide whether such a device reaches routine care, and this week the two largest medical markets showed how differently they handle the three.

On 13 March 2026 China's National Medical Products Administration granted market approval to NEO, an implantable brain-computer interface for hand motor function developed by Neuracle, known in Chinese as Boruikang, with Tsinghua University. On 2 September 2026 the US National Security Commission on Emerging Biotechnology published an analysis that called it the world's first commercial approval of an implanted BCI and listed four missing US mechanisms. The same week brought a Chinese magazine profile claiming 1,951 Chinese characters decoded from an implant, and a Taiwanese report on a US company that wants to read the brain through the nose. This Monitor reads the cluster for what each item can support.